Clark Anderson

Clark Anderson, MD, is Professor Emeritus in the Division of Rheumatology and Immunology, Department of Internal Medicine at The Ohio State University. He received his MD from the University of Chicago School of Medicine in 1964, following undergraduate studies in liberal arts at Brown University and the University of Arizona. He completed postgraduate training in internal medicine at the University of Colorado and postdoctoral research in immunochemistry at National Jewish Hospital in Denver, Colorado. After serving in the U.S. Army as a physician during the Vietnam War era, he joined the faculty at the University of Rochester in 1977. In 1986, he moved to The Ohio State University as professor in the Departments of Internal Medicine, Molecular and Cellular Biochemistry, and Molecular Genetics, achieving emeritus status effective June 1, 2005. His career was supported by continuous NIH R01 grants for over 40 years, including a Leukemia Society of America Special Fellowship (1975-1977) and an NIAID Research Career Development Award (1979-1984). He served on the NIH Medical Biochemistry Study Section (1987-1991) and received The Ohio State University Distinguished Scholar Award in 1994. Anderson has participated in university panels, including a 2019 CARE panel on conflicts of interest in research.

Anderson's research has centered on the mechanisms by which IgG antibodies mediate effects through Fc gamma receptors, IgG catabolism and protection by the neonatal Fc receptor (FcRn), albumin homeostasis, and clearance of blood-borne particles, viruses, and LPS by liver sinusoidal endothelial cells. He identified key Fc gamma receptors, developed monoclonal antibodies such as mAb 32 and IV.3 (U.S. Patent 4,954,617, 1990), confirmed FcRn's role in prolonging IgG and albumin lifespan (binding stoichiometries 2:1:1), and demonstrated liver sinusoidal endothelial cells eliminate up to 100 million HIV-like particles per minute in mice via second-order kinetics and scavenger receptor SR-BI with HDL. With over 200 publications and thousands of citations, notable works include 'Human leukocyte IgG Fc receptors' (Immunol Today, 1986), 'The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor' (PNAS, 1996), 'The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan' (J Exp Med, 2003), 'Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene' (PNAS, 2006), 'Rapid and Efficient Clearance of Blood-borne Virus by Liver Sinusoidal Endothelium' (PLoS Pathog, 2011), and 'Blood-borne lipopolysaccharide is rapidly eliminated by liver sinusoidal endothelial cells via high-density lipoprotein' (J Immunol, 2016). His findings have shaped immunology, influenced biopharmaceutical strategies for protein half-life extension, and corrected misconceptions about Kupffer cell dominance in clearance.

Professional Email: anderson.48@osu.edu